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Correspondence National Spending onCardiovascular Disease, 1996–2008To the Editor: In spite of great strides made in recent years to
improve its prevention and treatment, cardiovascular disease
(CVD) remains the most costly contributor to national health
expenditures (1,2). As part of an effort to improve our understand-
ing of the appropriate allocation of resources among CVD treat-
ment, prevention, and research, we have developed estimates of
national spending on CVD.
We include as CVD those conditions within International
Classification of Diseases-10th Edition (ICD-10) Chapter IX
(diseases of the circulatory system, ICD-10 I00-I99) and hyper-
lipidemia (ICD-10 E75, E78), the latter because of its close
association with CVD. We develop time series estimates of the
portion of the National Health Expenditure Accounts (NHEA)
devoted to prevention, treatment, and research associated with
these conditions. The NHEA, which are produced by the Center
for Medicare and Medicaid Services, are the U.S. government’s
official estimates of national health care spending (3). Because the
NHEA are not reported by condition nor partitioned into preven-
tion and treatment expenditures, we use supplementary data and
methods to develop the expenditure estimates reported here.
To estimate treatment expenditures, we use methods and data
described by Roehrig et al. (1). Briefly, we decompose NHEA
personal health spending estimates for each year into cells defined
by service type (hospital care, physician and clinical services,
prescription drugs, and so on) and population segment (civilian
noninstitutionalized population, nursing home residents, and so
on). For each year, we use supplementary data to estimate how
each cell’s personal health spending was distributed across medical
conditions and add results across all cells to produce annual
personal health spending by condition. We include spending on
hyperlipidemia in the presence of CVD as treatment expenditures.
Similarly, we count spending on hypertension (ICD-10: I10-13,
I15, I67.4) as treatment only if it is in the presence of other CVD.
We use data from the Medical Expenditure Panel Survey (MEPS)
to identify the portion of expenditures on hypertension and
hyperlipidemia that is associated with patients with CVD. MEPS
is a product of the Agency for Healthcare Research and Quality
that provides detailed estimates of healthcare utilization and
spending by the U.S. civilian noninstitutional population (4).
Our estimates of prevention expenditures are based on methods
nd data described by Miller et al. (5,6). Using data gleaned from
he literature and national data sets such as MEPS, we include
stimates of spending for counseling, screening (for hyperlipidemia
s well as for CVD), and treatment of hypertension and hyperlip-
demia in the absence of other CVD (using MEPS data to
istinguish spending for these conditions in patients without
VD).
For research expenditures, we use estimates from the National
nstitutes of Health (NIH) to identify the fraction of NHEA
esearch expenditures that are devoted to CVD and to partitionresearch into treatment versus prevention of CVD (7). In addition,
we note that commercial research spending (e.g., by pharmaceu-
tical and device manufacturers) is included in the NHEA within
expenditures for treatment and prevention interventions, because
that is how industry recovers the cost of this research. We have
developed separate estimates of this portion of research spending
by combining the NIH estimates with data reported by Moses et
al. (8), including updates for the most recent years from some of
Moses’ sources. Moses’ estimates are based on data published by
biotechnology trade organizations. Because these data are not
broken out by medical condition, we assume this distribution is
similar to that reported for NIH spending.
Our results are summarized in Table 1. For each year from 1996
through 2008 (the most recent year for which all source data were
available), we show CVD expenditures in current year dollars
broken down into treatment, prevention, treatment research, and
prevention research, with a further breakout of prevention and
treatment for specific conditions or risk factors. We also express
these results as the percentage of total CVD spending and
percentage of total NHEA contributed by each of these compo-
nents. The final 4 lines of the table consist of estimates of the
portion of treatment and prevention expenditures that are re-
invested into research, as well as total research spending including
this commercial research.
Since 1996, overall spending on CVD has grown at a compound
annual growth rate of 5.7%. This is somewhat less than the overall
rate of growth of the NHEA during the same period (6.8%) and
is due to the slower growth rate of spending on CVD treatment
(4.8%). (For comparison, updates to the results of Roehrig et al.
[1] suggest that spending on diabetes and cancer has grown over
the same time at rates of 8.5% and 7.3%, respectively.) As a result,
CVD spending as a percentage of the NHEA has declined
moderately. The relatively slow growth rate in CVD treatment
expenditures might be related to the long-term decline in smoking.
It might also be related to the increased capability and aggressive-
ness associated with treating hypertension and hyperlipidemia. In
fact, the more rapid growth rate of CVD prevention spending
(9.9%) is largely attributable to the growing emphasis on treating
these 2 CVD risk factors.
As a percentage of total CVD spending, spending on CVD
prevention is much higher than the 8% to 9% of total NHEA
spending attributable to prevention that is estimated elsewhere
(3,4). This is because our estimates of CVD prevention spending
include treatment for hypertension and hyperlipidemia in patients
without diagnosed CVD. We estimate that expenditures to pre-
vent CVD have grown to become more than 20% of total CVD
expenditures. (We recognize, however, that some clinicians and
researchers would consider hypertension and hyperlipidemia to be
conditions rather than risk factors. Our breakout in Table 1 allows
all hypertension and hyperlipidemia spending to be reallocated to
Table 1 National Spending on Cardiovascular Disease
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Expenditures (billions of dollars)
Treatment $133.6 $138.2 $143.2 $148.7 $153.3 $161.4 $166.6 $183.0 $192.0 $203.2 $205.0 $223.0 $234.4
Heart conditions $81.0 $80.7 $81.6 $83.0 $87.2 $91.4 $94.2 $106.8 $111.1 $119.6 $117.0 $129.5 $137.1
Coronary heart disease $53.5 $51.1 $50.5 $48.8 $50.4 $54.4 $55.2 $61.8 $63.0 $67.6 $69.4 $77.2 $82.6
Congestive heart failure $12.3 $13.5 $15.1 $14.9 $15.8 $15.5 $17.6 $18.7 $20.7 $23.2 $24.2 $24.5 $24.7
Dysrhythmias $12.6 $13.6 $12.0 $13.5 $13.6 $15.1 $16.4 $19.0 $20.0 $20.6 $19.4 $22.3 $24.4
Cerebrovascular disease $22.9 $23.0 $23.8 $24.2 $24.6 $24.0 $24.0 $24.9 $26.5 $26.0 $30.2 $33.3 $38.0
Prevention $22.1 $25.4 $27.5 $30.4 $33.9 $37.9 $43.3 $47.9 $52.7 $57.2 $61.3 $66.2 $68.3
Hypertension $13.3 $15.3 $16.4 $18.0 $19.8 $21.8 $24.0 $25.9 $28.0 $30.2 $30.7 $31.3 $30.5
Hyperlipidemia $4.0 $4.9 $5.4 $6.5 $7.7 $9.2 $11.5 $13.9 $16.4 $18.2 $21.0 $24.5 $26.9
Treatment research $1.0 $1.1 $1.2 $1.3 $1.4 $1.6 $1.8 $2.0 $2.2 $2.3 $2.3 $2.4 $2.4
Prevention research $0.2 $0.2 $0.2 $0.2 $0.3 $0.3 $0.3 $0.4 $0.4 $0.4 $0.4 $0.4 $0.5
Total $156.9 $164.8 $172.1 $180.6 $188.9 $201.2 $212.1 $233.2 $247.3 $263.0 $269.0 $291.9 $305.6
Expenditures (percentages of total)
Treatment 85.1% 83.8% 83.2% 82.3% 81.2% 80.2% 78.6% 78.5% 77.7% 77.2% 76.2% 76.4% 76.7%
Heart conditions 51.6% 48.9% 47.4% 46.0% 46.2% 45.4% 44.4% 45.8% 44.9% 45.5% 43.5% 44.4% 44.8%
Coronary heart disease 34.1% 31.0% 29.3% 27.0% 26.7% 27.0% 26.0% 26.5% 25.5% 25.7% 25.8% 26.4% 27.0%
Congestive heart failure 7.9% 8.2% 8.8% 8.2% 8.4% 7.7% 8.3% 8.0% 8.4% 8.8% 9.0% 8.4% 8.1%
Dysrhythmias 8.1% 8.3% 7.0% 7.4% 7.2% 7.5% 7.7% 8.1% 8.1% 7.8% 7.2% 7.6% 8.0%
Cerebrovascular disease 14.6% 14.0% 13.8% 13.4% 13.0% 12.0% 11.3% 10.7% 10.7% 9.9% 11.2% 11.4% 12.4%
Prevention 14.1% 15.4% 16.0% 16.8% 17.9% 18.8% 20.4% 20.5% 21.3% 21.7% 22.8% 22.7% 22.4%
Hypertension 8.5% 9.3% 9.5% 9.9% 10.5% 10.8% 11.3% 11.1% 11.3% 11.5% 11.4% 10.7% 10.0%
Hyperlipidemia 2.6% 3.0% 3.2% 3.6% 4.1% 4.6% 5.4% 5.9% 6.6% 6.9% 7.8% 8.4% 8.8%
Treatment research 0.6% 0.7% 0.7% 0.7% 0.8% 0.8% 0.8% 0.8% 0.9% 0.9% 0.9% 0.8% 0.8%
Prevention research 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.2% 0.2% 0.2% 0.2% 0.2% 0.2% 0.1%
Expenditures (percentages of national health expenditures)
Treatment 12.3% 12.1% 11.9% 11.6% 11.1% 10.8% 10.2% 10.3% 10.1% 10.1% 9.5% 9.8% 9.8%
Heart conditions 7.5% 7.1% 6.8% 6.5% 6.3% 6.1% 5.8% 6.0% 5.9% 5.9% 5.4% 5.7% 5.7%
Cerebrovascular disease 2.1% 2.0% 2.0% 1.9% 1.8% 1.6% 1.5% 1.4% 1.4% 1.3% 1.4% 1.5% 1.6%
Prevention 2.0% 2.2% 2.3% 2.4% 2.5% 2.5% 2.6% 2.7% 2.8% 2.8% 2.8% 2.9% 2.9%
Hypertension 1.2% 1.3% 1.4% 1.4% 1.4% 1.5% 1.5% 1.5% 1.5% 1.5% 1.4% 1.4% 1.3%
Hyperlipidemia 0.4% 0.4% 0.4% 0.5% 0.6% 0.6% 0.7% 0.8% 0.9% 0.9% 1.0% 1.1% 1.1%
Treatment research 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1%
Prevention research 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Total 14.5% 14.4% 14.2% 14.0% 13.7% 13.5% 13.0% 13.2% 13.1% 13.0% 12.5% 12.8% 12.8%
Treatment and prevention expenditures subsequently invested
in commercial research
Treatment research $1.3 $1.4 $1.6 $1.8 $1.9 $2.4 $2.6 $3.1 $3.0 $3.4 $3.3 $3.9 $4.3
Prevention research $0.2 $0.3 $0.3 $0.3 $0.4 $0.4 $0.5 $0.6 $0.6 $0.6 $0.6 $0.7 $0.8
Total research investment
Treatment research $2.3 $2.5 $2.8 $3.1 $3.4 $4.0 $4.4 $5.0 $5.2 $5.7 $5.7 $6.3 $6.7
Prevention research $0.4 $0.5 $0.5 $0.6 $0.6 $0.7 $0.8 $0.9 $1.0 $1.1 $1.1 $1.2 $1.3
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vention expenditures to drop to 3.6% of the total in 2008.)
Spending on CVD research is small, representing roughly 1% of
total CVD spending in recent years. (For comparison, spending on
cancer research represents more than 5% of total spending on
cancer, both because spending on cancer research is much greater
than on CVD research and because spending on cancer treatment
is less than on CVD treatment.) If commercial research spending
is included in the total, both total research expenditures and their
annualized growth rate (9.4%) are considerably larger. (As noted
earlier, however, commercial research spending is also included in
the expenditures for CVD treatment and prevention.)
Differences in our estimates from those of other researchers are
attributable to differences in methods and in what is being
counted. For example, our estimate of CVD spending for 2007 is
significantly larger than that of Roger et al. (9) primarily because
our estimates include spending by nursing home residents and
other institutionalized individuals in addition to the civilian,
noninstitutionalized population that is the focus of their estimates.
Our estimates also differ from others in that we separately capture
prevention and research expenditures and include a time series that
allows tracking trends in spending.
Our objective in this correspondence is to present estimates of
CVD spending that will contribute to a more informed discussion
of our nation’s allocation of healthcare resources to CVD treat-
ment, prevention, and research. However, this quantification of
expenditures does not address the question of whether the money
has been well spent. Cohen et al. (10) observe that the variation in
cost-effectiveness across different preventive interventions is ex-
treme and is similar to that found for different treatment inter-
ventions, suggesting that opportunities for improving the overall
cost-effectiveness of health expenditures through the reallocation
of resources exist, both within and between the broad categories of
prevention and treatment. Our analysis of a subset of these
interventions that focus on treatment and prevention of CVD
leads to a similar conclusion. Ongoing research (including the
research program that led to these estimates) is beginning to
address these issues in more detail, but much work remains to be
done to develop an understanding of the most cost-effective
allocation of resources to CVD and among CVD treatment
interventions, prevention interventions, and research to improve
the efficacy of these interventions.*George Miller, PhD
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